Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,670.00    12.00 (0.72%)
Bid:
1,666.00
Ask:
1,674.00
Spread: 8.00 (0.48%)
Market Cap: £491.84m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Post Close Half Year Trading Update

6 Apr 2022 07:00

RNS Number : 3970H
Avon Protection PLC
06 April 2022
 

6 April 2022

Avon Protection plc

Post Close Half Year Trading Update

 

Avon Protection plc ("Avon Protection" or "the Group") today provides the following trading update for the six months ended 31 March 2022 ("HY22" or the "Period"). Unless otherwise stated, figures and commentary exclude the armor business.

 

Trading update

 

Trading in the first half reflects a continuation of some of the challenges seen in FY21, but with performance accelerating through the second quarter. Order intake was, as expected, lower than the comparable period last year reflecting a very strong first half in 2021, but, following the events in Ukraine, enquiries remain robust giving us confidence in order intake for the second half and beyond. Revenue for the Period was in line with expectations and ahead overall by c. 4%, with organic year-on-year performance broadly flat.

 

Profitability has however been impacted, in broadly even proportions, by a weaker than expected sales mix in the first half and additional manufacturing costs, notably in the helmets business, due to supply chain and process inefficiencies. As a result, the adjusted EBITDA margin for the period is expected to be approximately 10%.

 

Operationally, we have made good progress on the implementation of the $15m overhead cost saving programme announced in December 2021 (of which approximately half relates to overheads in the armor business and the remainder relates to the rest of the Group), including the closure of one of our U.S. offices and a change in management structure which streamlines the organisation into one focussed business.

 

Strategically, we are pleased with our continued progress, which includes the award of the U.S. DLA contract for the second-generation Advanced Combat Helmet in February and delivery of the next-generation Integrated Head Protection System for first article test scheduled for Q3. This momentum further reinforces our position as a leading provider of head protection to the U.S. military and provides a strong platform for future growth.

 

Outlook

 

The recent events in Ukraine have highlighted the criticality of our products and capabilities, and we have seen a notable increase in customer enquiry activity.

 

We have a number of active discussions ongoing with customers regarding potential incremental orders across both respiratory and helmet products. While these discussions remain ongoing and the quantum and timing of resultant orders are still to be determined, the impact of this growth in demand is most likely to be seen in FY23 and beyond, and as such the Board continues to have a range of expected full year revenue outcomes for FY22 consistent with market expectations.

 

Profitability in H2 is expected to improve versus H1 but will not offset the weakness experienced in the Period. Full year underlying earnings will therefore be lower than previously expected.

 

The second half margin will benefit from the adverse mix impact substantially unwinding along with the operational gearing effect of higher revenues and the initial contribution from the cost saving initiatives. The manufacturing inefficiencies described above are expected to improve as higher volumes are achieved. As a result, the Board expects EBITDA margins to recover progressively through the second half of the financial year and beyond, with the extent of this improvement in part dependent on the quantum and timing of incremental orders. Looking forward into FY23, the Group's profitability will benefit from the improved FY22 exit run-rate and the full year effect of the cost savings.

 

Armor business

 

In the period, as expected, armor revenues were in the low single digit $m pending final sign-off of first article testing of the DLA ESAPI body armor product. Combined with overheads, this business therefore operated at an EBITDA loss in the first half. We have continued with our steps for an orderly exit of this business once existing contracts are satisfied.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"At Avon Protection, our purpose is to protect people and save lives. As a global leader in military-grade respiratory and head protection, we are seeing an increased demand for our products for both the short and longer term. We are working proactively with our key customers to confirm their requirements and maximise our available capacity in the short term. Longer term, this will create further opportunities and will likely result in mid-term capacity expansion to meet expected demand."

 

 

Notice of Results

The Group will release its results for the half year ended 31 March 2022 on 24 May 2022.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Rich Cashin, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection designs and produces life critical personal protection solutions for the world's militaries and first responders. With a portfolio that includes Chemical, Biological, Radiological, Nuclear ("CBRN"), respiratory and head protection products, Avon Protection's mission is to relentlessly advance the future of protection enhancing the performance, efficiency and capability of their customers whilst providing ever increasing levels of protection.

Avon Protection operates from six locations employing approximately 1,000 people and is listed on the London Stock Exchange (LSE: AVON).

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFFFSISLIEIIF
Date   Source Headline
13th May 20267:00 amRNSInterim Results
8th May 20267:00 amRNSHolding(s) in Company
6th May 20262:03 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSHolding(s) in Company
14th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Apr 202612:15 pmRNSHolding(s) in Company
8th Apr 202611:47 amRNSDirector/PDMR Shareholding
27th Mar 20261:23 pmRNSDirector/PDMR Shareholding
6th Mar 20261:23 pmRNSDirectors'/PDMR Shareholdings
6th Mar 20267:00 amRNSNew Filter Order
3rd Mar 20262:34 pmRNSHolding(s) in Company
13th Feb 202611:01 amRNSDirector/PDMR Shareholding
6th Feb 20262:52 pmRNSDirectors'/PDMR Shareholdings
6th Feb 20262:41 pmRNSFinal Dividend Currency Exchange Rate
4th Feb 20264:18 pmRNSHolding(s) in Company
2nd Feb 202610:10 amRNSResult of AGM
30th Jan 20267:00 amRNSAGM & Q1 Trading Update
20th Jan 20263:19 pmRNSDirector/PDMR Shareholding
6th Jan 20261:46 pmRNSDirectors'/PDMR Shareholdings
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
16th Dec 20258:45 amRNSHolding(s) in Company
11th Dec 20253:51 pmRNSHolding(s) in Company
11th Dec 20257:00 amRNSEuropean FM50 Order
9th Dec 202511:58 amRNSDirectors'/PDMR Shareholding
8th Dec 20251:32 pmRNSDirectors'/PDMR Shareholdings
5th Dec 20259:00 amRNSNotice of Annual Report & Accounts and AGM 2026
1st Dec 20256:01 pmRNSDirector Declaration
25th Nov 20253:55 pmRNSHolding(s) in Company
21st Nov 20259:50 amRNSNotification of LTIP & DSBP Awards
12th Nov 20257:00 amRNSPreliminary Results
7th Nov 20259:23 amRNSDirectors'/PDMR Shareholdings
16th Oct 20257:00 amRNSNotice of Results & Investor Presentation via IMC
8th Oct 202510:06 amRNSDirectors'/PDMR Shareholding
15th Sep 20252:51 pmRNSHolding(s) in Company
11th Sep 20254:10 pmRNSHolding(s) in Company
8th Sep 20251:14 pmRNSDirectors'/PDMR Shareholding
13th Aug 20254:59 pmRNSInterim Dividend Currency Exchange Rate
11th Aug 20254:47 pmRNSHolding(s) in Company
7th Aug 20253:10 pmRNSDirectors'/PDMR Shareholdings
17th Jul 20257:00 amRNSDirectors'/PDMR Shareholdings
23rd Jun 20257:00 amRNSUK MoD respirator order for Ukraine
10th Jun 20257:00 amRNSHolding(s) in Company
9th Jun 20259:30 amRNSDirectors'/PDMR Shareholdings
5th Jun 20253:31 pmRNSUS Department of Defense Order
3rd Jun 20256:00 pmRNSRenewi
29th May 202510:00 amRNSHolding(s) in Company
21st May 20257:00 amRNSInterim Results
20th May 20254:00 pmRNSNotification of change in particulars of director
16th May 20253:00 pmRNSNotification of change in particulars of director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.